Li Yaqi, Fan Xingwen, Pei Yulei, Yu Qi, Lu Renquan, Jiang Guoliang, Wu Kailiang
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
Transl Lung Cancer Res. 2024 Jun 30;13(6):1190-1200. doi: 10.21037/tlcr-24-60. Epub 2024 Jun 27.
Chemotherapy and radiotherapy (RT) would induce lymphopenia, leading to a poor prognosis. This study investigated whether chemotherapy increased lymphopenia during RT and explored the impacts of different chemotherapy regimens on the lymphocyte counts of patients receiving RT.
Clinical parameters and lymphocyte data were collected from 215 patients with locally advanced non-small cell lung cancer (LA-NSCLC). Severe lymphopenia (SRL) was defined as an absolute lymphocyte count (ALC) of ≤0.2×10 cells/μL. Patient overall survival (OS) was analyzed using the Kaplan-Meier method. The predictors of SRL were extracted using univariate and multivariate regression analyses with backward likelihood ratio elimination.
Compared with patients without SRL, patients with SRL with LA-NSCLC showed a poorer prognosis in terms of OS (P=0.003). Of the 215 patients, 130 underwent concurrent chemoradiotherapy (CCRT) and 85 underwent sequential chemoradiotherapy (SCRT). The OS was better in patients without SRL (in the CCRT group, P=0.01 and in the SCRT group, P=0.08). The mean ALCs for CCRT and SCRT did not differ significantly (P=0.27). The minimum ALC of CCRT was significantly lower than that of SCRT (P<0.0001). CCRT was a predictor of SRL (P=0.008). However, multivariate analysis showed that the different chemotherapy regimens were not predictors of SRL (all P>0.1).
In LA-NSCLC, the outcomes of patients with SRL were poorer than those without SRL. RT and chemotherapy were the main factors affecting SRL development, while different chemotherapy regimens were not significantly associated with lymphocyte counts in LA-NSCLC.
化疗和放疗会导致淋巴细胞减少,从而预后不良。本研究调查了化疗是否会在放疗期间加重淋巴细胞减少,并探讨了不同化疗方案对接受放疗患者淋巴细胞计数的影响。
收集了215例局部晚期非小细胞肺癌(LA-NSCLC)患者的临床参数和淋巴细胞数据。严重淋巴细胞减少(SRL)定义为绝对淋巴细胞计数(ALC)≤0.2×10⁹细胞/μL。采用Kaplan-Meier法分析患者总生存期(OS)。使用单因素和多因素回归分析及向后似然比消除法提取SRL的预测因素。
与无SRL的LA-NSCLC患者相比,有SRL的患者在OS方面预后较差(P = 0.003)。215例患者中,130例接受同步放化疗(CCRT),85例接受序贯放化疗(SCRT)。无SRL的患者OS较好(CCRT组中,P = 0.01;SCRT组中,P = 0.08)。CCRT和SCRT的平均ALC无显著差异(P = 0.27)。CCRT的最低ALC显著低于SCRT(P < 0.0001)。CCRT是SRL的一个预测因素(P = 0.008)。然而,多因素分析表明,不同的化疗方案不是SRL的预测因素(所有P > 0.1)。
在LA-NSCLC中,有SRL的患者预后比无SRL的患者差。放疗和化疗是影响SRL发生的主要因素,而不同的化疗方案与LA-NSCLC患者的淋巴细胞计数无显著相关性。